Condition: Hemophilia A With Inhibitor · Hemophilia A Without Inhibitor · Hemophilia A, Severe · Sponsor: Kathelijn Fischer
The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.
This description comes directly from the study's public registry record.
Kathelijn Fischer, Dr, MD. · +318 875 584 50 · k.fischer@umcutrecht.nl
Konrad VD van der Zwet, MD · +31650124691 · k.vanderzwet@umcutrecht.nl
Always discuss trial participation with your own doctor first.
| Radboud University Medical Center | Nijmegen, Gelderland, Netherlands | Recruiting |
| Maastricht University Medical Center | Maastricht, Limburg, Netherlands | Recruiting |
| Amsterdam University Medical Center | Amsterdam, North Holland, Netherlands | Recruiting |
| Leids Universitair Medisch Centrum | Leiden, South Holland, Netherlands | Recruiting |
| Erasmus University Medical Center | Rotterdam, South Holland, Netherlands | Recruiting |
| HagaZiekenhuis | The Hague, South Holland, Netherlands | Recruiting |
| University Medical Center Groningen | Groningen, Netherlands | Recruiting |
| University Medical Center Utrecht | Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06320626